99 related articles for article (PubMed ID: 27402142)
1. Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis.
Zou Y; Xiao J; Lu XX; Xia ZA; Xie B; Li J; Chen Q
Clin Respir J; 2018 Jan; 12(1):269-278. PubMed ID: 27402142
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis.
Wang J; Jin D; Zuo P; Wang T; Xu Y; Xiong W
Respirology; 2011 Feb; 16(2):350-8. PubMed ID: 21138499
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
4. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
Karner C; Cates CJ
Cochrane Database Syst Rev; 2012 Apr; 4(4):CD008989. PubMed ID: 22513969
[TBL] [Abstract][Full Text] [Related]
5. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD.
Yildiz BP; Bayraktaroglu M; Gunen H
Curr Med Res Opin; 2019 Dec; 35(12):2187-2196. PubMed ID: 31397184
[No Abstract] [Full Text] [Related]
6. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia.
Lee SD; Xie CM; Yunus F; Itoh Y; Ling X; Yu WC; Kiatboonsri S
Respirology; 2016 Jan; 21(1):119-27. PubMed ID: 26394882
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
10. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis.
Tang B; Wang J; Luo LL; Li QG; Huang D
Med Sci Monit; 2019 Feb; 25():1155-1163. PubMed ID: 30747109
[TBL] [Abstract][Full Text] [Related]
12. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.
Kim JS; Park J; Lim SY; Oh YM; Yoo KH; Park YB; Sheen SS; Kim MJ; Carriere KC; Jung JY; Park HY
PLoS One; 2015; 10(3):e0119948. PubMed ID: 25799171
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the rapid effects of single inhalations of formoterol and tiotropium bromide on respiratory function and COPD symptoms in a randomized crossover study.
Ohbayashi H
Respir Investig; 2017 Nov; 55(6):348-356. PubMed ID: 29153415
[TBL] [Abstract][Full Text] [Related]
15. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
16. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.
Di Marco F; Verga M; Santus P; Morelli N; Cazzola M; Centanni S
Respir Med; 2006 Nov; 100(11):1925-32. PubMed ID: 16626956
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
19. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]